{
    "doi": "https://doi.org/10.1182/blood-2019-122878",
    "article_title": "Gene Therapy for Lad-I Immunodeficiency: Preclinical Evaluation of HSC Transduction Under Optimized GMP-Conditions ",
    "article_date": "November 13, 2019",
    "session_type": "801.Gene Therapy and Transfer",
    "abstract_text": "The efficacy of lentiviral gene therapy for the treatment of primary immunodeficiencies (PIDs) has been extensively demonstrated in diseases such as X1-SCID, ADA-SCID, X-CGD and WAS. Leukocyte Adhesion Deficiency type I (LAD-I) has also emerged as a PID that is potentially correctable by gene therapy. To this aim during the recent years we have completed all the pre-clinical work required for the initiation of a gene therapy trial for patients with severe LAD-I. Mutations in the ITGB2 gene (encoding for the \u03b22 subunit of integrins, also known as CD18) impair leukocyte extravasation to inflamed areas. LAD-I patients thus suffer from recurrent and life-threatening bacterial and fungal infections. We have previously demonstrated that the ectopic expression of CD18 driven by a myeloid chimeric promoter in LAD-I leukocytes restores their ability to migrate to inflamed sites. Because the efficacy of hematopoietic gene therapy relies on the stable engraftment of gene-corrected HSCs in treated patients, we have implemented the transduction conditions of human HSCs with this therapeutic lentiviral vector in healthy donor CD34 + cells, either from cord blood or mobilized peripheral blood sources. CD34 + cells were transduced at relatively low multiplicities of infection (MOIs) of 50 i.u./cell in the presence of transduction enhancers. Using an optimized transduction protocol, high transduction efficacies were obtained with minimal loss in hematopoietic progenitors. On average, transduction efficiencies of 70% and mean vector copy numbers of 2-5 copies/cell were identified in hematopoietic progenitor cells. Similar results were obtained when large-scale GMP conditions were used. To assess the transduction efficacy of human HSCs, transduced CD34 + cells were transplanted into immunodeficient NSG mice. In these studies, stable repopulation levels of human cells harboring 1-3 copies of the therapeutic vector per cell were observed up to three months post transplantation. In some cases, secondary transplants were also performed, confirming long-term and stable engraftment of transduced cells. These results have allowed us to obtain the approval for the initiation of the first lentiviral-mediated gene therapy clinical trial for the treatment of LAD-I patients. Disclosures Almarza: Rocket Pharmaceuticals: Equity Ownership, Patents & Royalties, Research Funding. Rio: Rocket Pharmaceuticals: Equity Ownership, Patents & Royalties, Research Funding. Law: Rocket Pharmaceuticals: Employment, Equity Ownership. Beard: Rocket Pharmaceuticals: Employment, Equity Ownership. Schwartz: Rocket Pharmaceuticals: Employment, Equity Ownership. Bueren: Rocket Pharmaceuticals, Inc.: Consultancy, Equity Ownership, Patents & Royalties: Inventor on patents on lentiviral vectors filled by CIEMAT, CIBERER and F.J.D and may be entitled to receive financial benefits from the licensing of such patents, Research Funding.",
    "topics": [
        "cyclic gmp",
        "gene therapy",
        "good manufacturing practice",
        "immunologic deficiency syndromes",
        "cd18 antigens",
        "cd34 antigens",
        "severe combined immunodeficiency",
        "extravasation of diagnostic and therapeutic materials",
        "infections",
        "integrins"
    ],
    "author_names": [
        "Elena Almarza, PhD",
        "Cristina Mesa-N\u00fa\u00f1ez, PhD",
        "Carlos Dami\u00e1n",
        "Mar\u00eda Fern\u00e1ndez-Garc\u00eda",
        "Bego\u00f1a D\u00edez-Cabezas, PhD",
        "M Luz Lozano",
        "Paula Rio, PhD",
        "Rosa M Ya\u00f1ez, PhD",
        "Ken Law, PhD",
        "Brian C Beard, PhD",
        "Jonathan D Schwartz, MD",
        "Juan A. Bueren, PhD"
    ],
    "author_dict_list": [
        {
            "author_name": "Elena Almarza, PhD",
            "author_affiliations": [
                "Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energ\u00e9ticas Medioambientales y Tecnol\u00f3gicas (CIEMAT) and Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras (CIBERER-ISCIII), Madrid, Spain ",
                "Instituto de Investigaci\u00f3n Sanitaria Fundaci\u00f3n Jim\u00e9nez D\u00edaz (IIS-FJD/UAM), Madrid, Spain "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Cristina Mesa-N\u00fa\u00f1ez, PhD",
            "author_affiliations": [
                "Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energ\u00e9ticas Medioambientales y Tecnol\u00f3gicas (CIEMAT) and Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras (CIBERER-ISCIII), Madrid, Spain ",
                "Instituto de Investigaci\u00f3n Sanitaria Fundaci\u00f3n Jim\u00e9nez D\u00edaz (IIS-FJD/UAM), Madrid, Spain "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Carlos Dami\u00e1n",
            "author_affiliations": [
                "Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energ\u00e9ticas Medioambientales y Tecnol\u00f3gicas (CIEMAT) and Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras (CIBERER-ISCIII), Madrid, Spain ",
                "Instituto de Investigaci\u00f3n Sanitaria Fundaci\u00f3n Jim\u00e9nez D\u00edaz (IIS-FJD/UAM), Madrid, Spain "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Mar\u00eda Fern\u00e1ndez-Garc\u00eda",
            "author_affiliations": [
                "Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energ\u00e9ticas Medioambientales y Tecnol\u00f3gicas (CIEMAT) and Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras (CIBERER-ISCIII), Madrid, Spain ",
                "Instituto de Investigaci\u00f3n Sanitaria Fundaci\u00f3n Jim\u00e9nez D\u00edaz (IIS-FJD/UAM), Madrid, Spain "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Bego\u00f1a D\u00edez-Cabezas, PhD",
            "author_affiliations": [
                "Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energ\u00e9ticas Medioambientales y Tecnol\u00f3gicas (CIEMAT) and Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras (CIBERER-ISCIII), Madrid, Spain ",
                "Instituto de Investigaci\u00f3n Sanitaria Fundaci\u00f3n Jim\u00e9nez D\u00edaz (IIS-FJD/UAM), Madrid, Spain "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "M Luz Lozano",
            "author_affiliations": [
                "Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energ\u00e9ticas Medioambientales y Tecnol\u00f3gicas (CIEMAT) and Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras (CIBERER-ISCIII), Madrid, Spain ",
                "Instituto de Investigaci\u00f3n Sanitaria Fundaci\u00f3n Jim\u00e9nez D\u00edaz (IIS-FJD/UAM), Madrid, Spain "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Paula Rio, PhD",
            "author_affiliations": [
                "Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energ\u00e9ticas, Medioambientales y Tecnol\u00f3gicas (CIEMAT), Madrid, Spain ",
                "Instituto de Investigaciones Sanitarias Fundaci\u00f3n Jim\u00e9nez D\u00edaz (IIS-FJD), Madrid, Spain "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Rosa M Ya\u00f1ez, PhD",
            "author_affiliations": [
                "Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energ\u00e9ticas Medioambientales y Tecnol\u00f3gicas (CIEMAT) and Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras (CIBERER-ISCIII), Madrid, Spain ",
                "Instituto de Investigaci\u00f3n Sanitaria Fundaci\u00f3n Jim\u00e9nez D\u00edaz (IIS-FJD/UAM), Madrid, Spain "
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Ken Law, PhD",
            "author_affiliations": [
                "Rocket Pharmaceuticals, Inc., New York, NY"
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Brian C Beard, PhD",
            "author_affiliations": [
                "Rocket Pharmaceuticals, Inc., New York, NY"
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Jonathan D Schwartz, MD",
            "author_affiliations": [
                "Rocket Pharmaceuticals, Inc., New York, NY"
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Juan A. Bueren, PhD",
            "author_affiliations": [
                "Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energ\u00e9ticas, Medioambientales y Tecnol\u00f3gicas (CIEMAT), Madrid, Spain ",
                "Instituto de Investigaciones Sanitarias Fundaci\u00f3n Jim\u00e9nez D\u00edaz (IIS-FJD), Madrid, Spain "
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-06-19T02:44:19",
    "is_scraped": "1"
}